Two Sigma Investments
IMMX icon

Two Sigma Investments’s Immix Biopharma IMMX Stock Holding History

Two Sigma Investments’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,862
Closed -$70.2K – 3168
2024
Q1 		$70.2K Buy
+22,862
New +$88.5K ﹤0.01% 2861

Other funds holding IMMX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments's IMMX Position: Q2 2024 in Review

Two Sigma Investments sold out of Immix Biopharma (IMMX) in Q2 2024, closing a stake of 22,862 shares — an estimated $70.2K sold.

Two Sigma Investments first reported a position in IMMX in Q1 2024 and held it in 1 quarter. The position peaked at $70.2K in Q1 2024. 31 funds tracked by Wall St. Rank hold IMMX as of Q2 2024.

  • Two Sigma Investments reported no remaining Immix Biopharma position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Investments sold 22,862 Immix Biopharma shares in Q2 2024, an estimated $70.2K.
  • Two Sigma Investments first reported a position in Immix Biopharma in Q1 2024 and held it in 1 quarter.
  • Two Sigma Investments's Immix Biopharma position peaked at $70.2K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.